טוען...
Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges
The coronavirus disease (COVID-19) pandemic is sweeping the globe. Even with a number of effective vaccines being approved and available to the public, new cases and escalating mortality are climbing every day. ACE2 (angiotensin-converting enzyme 2) is the primary receptor for the COVID-19 causative...
שמור ב:
| הוצא לאור ב: | Am J Respir Cell Mol Biol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Thoracic Society
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8008810/ https://ncbi.nlm.nih.gov/pubmed/33296619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1165/rcmb.2020-0322PS |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|